GLP1R and Insulin resistance: Integrated care teams can synergize liver-specific interventions (e.g., fibrosis monitoring via FIB-4/VCTE) with cardiovascular risk reduction strategies (e.g., lipid control, GLP-1 agonists), while endocrinologists address underlying metabolic dysfunction (e.g., insulin resistance).